ResearcherMayo ClinicActive in the last 2 years

Nayef Hikmat Abdel-Razeq

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-2452-2194; OpenAlex author ID A5038009535, A5054296140. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance. Co-author DOI 10.21037/apc-26-0044 ↗
Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years. Co-author DOI 10.1080/13543784.2025.2473698 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hani M. Babiker · 2 shared papers, 2025–2026 · strength 0.87
- Paper Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance. DOI 10.21037/apc-26-0044 ↗
- Paper Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years. DOI 10.1080/13543784.2025.2473698 ↗
Debabrata Mukhopadhyay · 1 shared paper, 2026 · strength 0.50
- Paper Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance. DOI 10.21037/apc-26-0044 ↗
Ahmed Adel Fouad Abdelhakeem · 1 shared paper, 2025 · strength 0.37
- Paper Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years. DOI 10.1080/13543784.2025.2473698 ↗
Osama M. Mosalem · 1 shared paper, 2025 · strength 0.37
- Paper Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years. DOI 10.1080/13543784.2025.2473698 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.